{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-022006","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.367214+00:00","generated_at":"2026-05-15T08:19:43.808320+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sangamo 2025 net loss $122.9M; cash only $20.9M; Fabry BLA rolling submission ongoing","bullets":["Consolidated 2025 net loss $122.9M ($0.44/sh); Q4 loss $37.4M ($0.11/sh).","Revenue in 2025 fell to $39.6M from $57.8M; Q4 revenue $14.2M up from $7.6M, driven by Pfizer and Lilly collaborations.","Cash and equivalents $20.9M as of Dec 31; expects funding into Q3 2026 after recent $25M offering and other receipts.","Rolling BLA submission to FDA for ST-920 (Fabry gene therapy) in progress; CMC module expected summer 2026 subject to funding.","Neurology pipeline advancing: Phase 1/2 STAND study for ST-503 in chronic pain with six sites activated; Eli Lilly capsid license added."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-022006","json":"https://secwatch.observer/filing/0001628280-26-022006.json","markdown":"https://secwatch.observer/filing/0001628280-26-022006.md","text":"https://secwatch.observer/filing/0001628280-26-022006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/sgmo-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:19:43.808320+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4828888f2aa4713265c2b5c545f445a9d3ae7c01","claim":"SANGAMO THERAPEUTICS, INC reported fourth quarter ended December 31, 2025 results: revenue $14.2 million, net income $37.4 million, EPS $0.11 per share.","evidence_excerpt":"to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$14.2 million"},{"label":"Net income","value":"$37.4 million"},{"label":"EPS","value":"$0.11 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fdd5d1f3b2170be665e0a12af0e680676f3c8371","claim":"SANGAMO THERAPEUTICS, INC reported year ended December 31, 2025 results: revenue $39.6 million, net income $122.9 million, EPS $0.44 per share.","evidence_excerpt":"For the year ended December 31, 2025, consolidated net loss was $122.9 million, or $0.44 per share, compared to consolidated net loss of $97.9 million, or $0.49 per share, for the year ended December 31, 2024. Revenues Revenues for the fourth quarter ended December 31, 2025 were $14.2 million, compared to $7.6 million for the same period in 2024. The increase of $6.6 million in revenues was primarily attributable to $6.0 million in revenue relating to Pfizer’s exercise of its option to obtain a license pursuant to the terms of the 2008 licensing agreement for certain zinc finger modified cell lines, an increase of $1.0 million in revenue relating to our collaboration agreement with Astellas, and $0.4 million in revenue from research services relating to our capsid license agreement with Lilly, partially offset by $0.8 million in revenue relating to our collaboration agreement with Genentech recognized in 2024. Revenues were $39.6 million in 2025, compared to $57.8 million in 2024. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/0001628280-26-022006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$39.6 million"},{"label":"Net income","value":"$122.9 million"},{"label":"EPS","value":"$0.44 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}